- Conditions
- COPD, Pulmonary Disease, Chronic Obstructive
- Interventions
- Collection of safety data for Cohort 1
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 26
- States / cities
- Anaheim, California • San Diego, California • Bay Pines, Florida + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–343
of 343
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Large B-cell Lymphoma
- Interventions
- cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
- Genetic · Drug · Device
- Lead sponsor
- Allogene Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 64
- States / cities
- Gilbert, Arizona • Hot Springs, Arkansas • Berkeley, California + 52 more
- Conditions
- Cutaneous Squamous Cell Carcinoma (CSCC)
- Interventions
- Short course radiation, Active Surveillance
- Radiation · Other
- Lead sponsor
- University of Vermont Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Breast Cancer
- Interventions
- E75 + GM-CSF vaccine
- Biological
- Lead sponsor
- COL George Peoples, MD, FACS
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2013
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Windber, Pennsylvania
- Conditions
- Hemophilia A
- Interventions
- Damoctocog alfa pegol (Jivi, Bay94-9027)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Not listed
- Enrollment
- 371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 10
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Davis, California + 7 more
- Conditions
- Solid Tumor
- Interventions
- ABSK061
- Drug
- Lead sponsor
- Abbisko Therapeutics Co, Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Japanese Encephalitis
- Interventions
- Japanese Encephalitis Virus vaccine, inactivated, adsorbed
- Biological
- Lead sponsor
- Valneva Austria GmbH
- Industry
- Eligibility
- 17 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Alexandria, Virginia